Trial Profile

A Phase 2 Clinical Trial of SBX 1977 for treatment of Wound

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Oct 2025 New trial record
28 Aug 2025 According to a Stramsen Biotech media release, FDA has acknowledged company's submission and has granted Pre-IND meeting set for September 16, 2025.
28 Aug 2025 According to a Stramsen Biotech media release, the company has successfully submitted a pre-Investigational New Drug (Pre-IND) meeting request, accompanied by a comprehensive Pre-IND package, to the U.S. Food and Drug Administration (FDA) for SBX1977. The company seeks FDA guidance on advancing directly to phase 2 clinical trials, waiving a separate phase 1 and expects that FDA concurrence with this assessment would enable the company to proceed directly to phase 2 trials.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com